Schmid is the executive director of the HIV+Hepatitis Policy Institute.
Advocates are pushing for federal action to ensure copay assistance counts toward patient deductibles, as insurers’ use of accumulator programs continues to drive up out-of-pocket costs. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, offers commentary to this unresolved issue.
As the spending bill makes its way through Congress, the HIV+Hepatitis Policy Institute's Carl Schmid provides some insights on the latest wranglings on the HIV bill and the domestic programs.
Carl Schmid on the US Supreme Court ruling, proposed Centers for Disease Control and Prevention cuts, stigma, and why equitable PrEP access, including new long-acting options, depends on more than insurance.
HIV+Hepatitis Policy Institute director discusses PrEP access, insurer compliance, and challenges ahead following the landmark decision.
Carl Schmid, executive director, HIV+Hepatitis Policy Institute, speaks to these closings.
A coalition of employers, the US Business Action to End HIV, sent a letter to Congress outlining the continued need for support from the federal government.
February 2nd 2026
